EICHORCondition: Diabetes Mellitus, Type 2 · Sponsor: Eli Lilly and Company
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Clinical Pharmacology of Miami | Hialeah, Florida, United States | — |
| Hassman Research Institute | Marlton, New Jersey, United States | — |
| Midwest Clinical Research Unit | Dayton, Ohio, United States | — |
| Endeavor Clinical Trials | San Antonio, Texas, United States | — |
| Profil Institut für Stoffwechselforschung | Neuss, North Rhine-Westphalia, Germany | — |
| Profil Mainz | Mainz, Germany | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04426474